Free Trial
$100 Off. Every Year. Lock In MarketBeat All Access at $149
Claim the Rate Lock
Claim MarketBeat All Access Sale Promotion
NASDAQ:EVGN

Evogene Q3 2026 Earnings Date & Estimates

Evogene logo
$0.38 +0.01 (+1.48%)
Closing price 04:00 PM Eastern
Extended Trading
$0.38 +0.00 (+0.03%)
As of 06:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Evogene is estimated to report Q3 2026 earnings on Thursday, November 19, 2026, before market opens. The conference call is scheduled for 9:00 AM ET.

Research:ProfileEarnings HistoryForecast

Upcoming Earnings Announcement

Quarter
Q3 2026
Announcement Date
Time
Before Market Opens
Conference Call
9:00 AM ET
Google Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab)

What Analysts Expect from Evogene in Q3 2026

Evogene is expected to post earnings of -$0.19 per share on revenue of $0.37 million. In the same quarter a year earlier Evogene reported -$0.31 per share on revenue of $0.31 million. Evogene last reported on May 16, 2026, posting -$0.60 per share and missing the -$0.27 consensus estimate. Evogene has beaten the consensus EPS estimate in 5 of its last 8 quarters.

Consensus Estimates

Consensus EPS
-$0.19
Expected Revenue
$0.37 million
Prior-Year EPS
-$0.31
Prior-Year Revenue
$0.31 million
Expected Revenue Growth
+17.0%

Recent Track Record

Last Reported
Q1 2026
Last Quarter EPS
-$0.60 (Missed by -$0.33)
Last Quarter Revenue
$0.33 million
EPS Beat Rate
5 of last 8 quarters

Prepare for the Q3 2026 Call

Evogene Q3 2026 Earnings FAQ

Evogene (NASDAQ:EVGN) is estimated to report Q3 2026 earnings on Thursday, November 19, 2026, before market opens. This date is estimated from past reporting schedules and may change once the company confirms it.

Evogene's Q3 2026 earnings conference call is scheduled for Thursday, November 19, 2026 at 9:00 AM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date.

Analysts expect Evogene to post earnings of -$0.19 per share for Q3 2026.

The consensus revenue estimate for Evogene is $0.37 million for Q3 2026.

Evogene Earnings Headlines

Evogene to Participate in U.S. East Coast AI Drug Discovery Roadshow Organized by the Israel Export Institute and TradeIL
October 20 at 8:00 AM  |  prnewswire.comhttps://www.prnewswire.com/news-releases/evogene-to-participate-in-us-east-coast-ai-drug-discovery-roadshow-organized-by-the-israel-export-institute-and-tradeil-302913966.html
Evogene (NASDAQ:EVGN) Shares Cross Below 200 Day Moving Average - Should You Sell?
October 17, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31127749
Federal Reserve’s Disturbing Plan To Control Your Money
A Federal Reserve filing, Docket No. OP-1670, is drawing scrutiny for language that could expand the Fed's visibility into consumer bank transactions. A pilot program is reportedly already underway, with wider rollout at major banks possibly beginning this summer. Martin D. Weiss, PhD, founder of Weiss Ratings, breaks down what the document says and what steps account holders might consider.tc pixel
October 22 at 1:00 AM  |  Weiss Ratings (Ad)
Evogene Ltd. (NASDAQ:EVGN) Shares Shorted: Short Interest Up 1,541.9% in September
October 11, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31108330
Evogene consensus price target decreased by 14.04% to ₪590.96
October 9, 2026  |  msn.comhttps://www.msn.com/en-us/money/top-stocks/evogene-consensus-price-target-decreased-by-14-04-to-590-96/ar-AA2dReLX
Evogene and Pure Capital Group Reach Cooperation Agreement to Resolve Differences and Reconstitute Board of Directors
October 6, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/evogene-and-pure-capital-group-reach-cooperation-agreement-to-resolve-differences-and-reconstitute-board-of-directors-302900213.html
See More Evogene Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Evogene? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Evogene and other key companies, straight to your email.

About Evogene

Evogene (NASDAQ:EVGN) is an Israel-based computational biology company that develops products and technologies for the life sciences and agriculture industries. Founded in 1999 and headquartered in Rehovot, Israel, the company uses its Computational Predictive Biology platform, which combines biological data, artificial intelligence and machine-learning tools to identify and develop novel biological products.

Evogene’s activities have included agricultural solutions such as crop-protection products, bio-stimulants and microbiome-based technologies. The company has pursued these opportunities through subsidiaries and business units including Lavie Bio, which focuses on microbiome-based agricultural products, and AgPlenus, which develops computationally designed crop-protection solutions. Its programs are intended to support applications such as improved crop performance, disease control and more sustainable agricultural production.

Evogene has also explored human-health applications through businesses such as Canonic, which focused on the development of medical cannabis products, and other microbiome-related research initiatives. The company’s technology and development programs are aimed at serving global agricultural and life-science markets through partnerships, product development and commercialization activities.

View Evogene Profile
Earnings Tools